<DOC>
	<DOCNO>NCT02353143</DOCNO>
	<brief_summary>The purpose study assess safety MEN1112 , give intravenous infusion , patient relapse refractory AML . Pharmacokinetics , clinical activity potential immunogenicity MEN1112 evaluate well .</brief_summary>
	<brief_title>Study MEN1112 Intravenous Infusion Relapsed Refractory Acute Myeloid Leukemia</brief_title>
	<detailed_description>This trial design open label , non randomise , dose escalation cohort expansion , first administration human study conduct approximately 20 European site . The study aim identify Dose Limiting Toxicity ( DLT ) Maximum Tolerated Dose ( MTD ) , assess pharmacokinetics determine clinical activity potential immunogenicity MEN1112 , administer IV infusion give every week 21 day cycle patient relapsed/refractory acute myeloid leukemia ( AML ) . Approximately 50 male female ≥ 18 years-old patient , document diagnosis relapse refractory AML ( M3 FAB subtype ) , treat study , consist two step . Step 1 dose escalation phase accord 3+3 patient cohort design.Incremental mg/Kg dos test give day 1 , 8 15 21-day cycle . Briefly , MEN1112 dose administer 3 patient ; DLT observe cohort 3 DLT evaluable patient give dose level , next cohort 3 new patient treat next high dose . In case DLT occurrence one three patient dose , cohort expand 6 DLT evaluable patient dose level . If two patient give dose level exhibit DLT , dose escalation phase conclude MTD identify one dose level one ≥ 2 DLT 6 treat patient occur . Step 2 cohort expansion phase include patient treated MTD maximum dose level judge tolerable . In study Step , patient give two induction cycle MEN1112 follow three week End Induction period . Patients undergo 4 post-induction/maintenance visit every 28 day ( maintenance administration allow patient achieve clinical benefit base Investigator 's judgement ) End Study Visit . Along study period , adverse event , change hematology/serum biochemistry parameter bone marrow treatment response represent major clinical finding monitor regular basis . The individual experimental clinical phase last 6 month ( except female patient childbearing potential undergo monthly pregnancy test 6 month last study drug administration ) encompass 40 planned visit site , include Screening , Induction , End Induction , Post-induction/Maintenance End Study visit .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Male female patient age ≥ 18 year . Documented definitive diagnosis AML ( accord WHO criterion , 2008 ) relapsed/refractory standard treatment , standard therapy available patient refuse standard therapy . WBC count ≤ 10 x 109/L Visit 1 ( Day 1 ) ; hydroyxurea allow low WBC count . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 2 Visit 1 ( Day 1 ) . Life expectancy least 2 month . Adequate renal hepatic laboratory assessment : Aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) alkaline phosphatase ( ALP ) ≤3.0 × ULN , unless consider due leukemic organ involvement , Total Bilirubin ≤2.0 × ULN , Serum creatinine ≤2.0 × ULN . Able give write informed consent study related procedure Acute promyelocytic leukaemia ( FrenchAmericanBritish M3 classification ) . Active central nervous system involvement . Haematopoietic stem cell transplantation ( HSCT ) perform within 3 month prior Screening Visit . Active infection require intravenous antibiotic . Lifethreatening illness AML , uncontrolled medical condition organ system dysfunction , investigator 's opinion , could compromise patient 's safety interfere patient 's ability comply study activity . Antitumour therapy within 14 day study Visit 1 ( Day 1 , exclude hydroxyurea ) . Prior participation investigational study ( procedure device ) within 21 day study Visit 1 ( Day 1 ) . Radiotherapy within 28 day prior study Visit 1 ( Day 1 ) schedule along study conduct . Known history human immunodeficiency virus ( HIV ) active infection hepatitis C virus ( HCV ) hepatitis B virus ( HBV ) . Other active malignancy . History malignancy last 12 month ( except basal cell squamous cell skin cancer carcinoma situ cervix breast nonmelanoma skin cancer ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Acute Myeloid Leukemia</keyword>
	<keyword>AML</keyword>
	<keyword>Relapsed</keyword>
	<keyword>Refractory</keyword>
	<keyword>MEN1112</keyword>
	<keyword>Monoclonal antibody</keyword>
</DOC>